A comparative study of probiotic, prokinetic based triple therapy with USFDA regimen in the eradication of Helicobacter pylori in a tertiary care hospital
Keywords:Helicobacter pylori, Probiotics, Prokinetics, Eradication rate, Safety, Compliance
Background: Helicobacter pylori infection has been associated with peptic ulcer disease, gastric carcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma. Its eradication is important and current regimens are associated with antibiotic resistance, side effects and poor patient compliance. Probiotics supplementation can overcome the above problem and additions of prokinetics improve dyspepsia symptoms and thereby improve patient compliance. So the aim of the study was to compare efficacy and safety of standard United States Food and Drug Administration (USFDA) regimen with probiotic, prokinetic based novel regimen.
Methods: 100 patients diagnosed with H. pylori infection were randomly assigned into two eradication regimen groups viz., group A and group B. Group A received standard USFDA regimen, amoxicillin 1 gm, lansoprazole 30 mg and clarithromycin 500 mg twice a day for 2 weeks and group B received a probiotic and prokinetic itopride 50 mg thrice daily, pantoprazole 40 mg, amoxicillin 1 gm and clarithromycin 500 mg twice daily for 2 weeks. Patients with Rapid Urease Test (RUT) and histopathology reports negative for H. pylori were considered as eradicated and then the percentage of eradication rate in both groups was compared.
Results: H. pylori eradication rates were more in group B compared to group A (84% vs 70%, p =0.096 at 95% CI). The occurrence of side effects was less in group B compared to group A (30% vs 46%, p= 0.099). Diarrhoea was statistically less in group B compared to group A (p< 0.05).
Conclusions: Probiotics supplementation increases eradication rates of anti H. pylori therapy and improves tolerability by reducing side effects especially diarrhoea. Prokinetics and probiotic based novel regimen improved dyspepsia symptoms and patient compliance.
Atherton JC, Blaser MJ. Helicobacter pylori infections. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL et al. Editors, Harrison’s Principles of Internal Medicine. Vol. 1, 17th ed. McGraw hill, New York. 2009:946-9.
Chey WD, Wong BCY and the Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology Guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808‐25.
Wannmacher L. Review of the evidence for H.pylori treatment regimens. 18th expert committee on the selection and use of essential medicines (Antacids and other antiulcer medicines) - adults and children. 2011;Section 17.1.
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III. Consensus Report Gut. 2007;56:772-81.
Kausik SP, Vu C. Helicobacter pylori eradication with lansoprazole, amoxicillin and clarithromycin: testing an ideal regimen in a multicultural south East Asian population and examining factors potentially influencing eradication. Aust N Z J Med. 2000;30(2):231-5.
Sheu SB, Cheng CH, Kao WA, Wang ST et al. Pretreatment with Lactobacillus and Bifidobacterium containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr. 2006;83:864-9.
Ang TL, Fock KM, Teo EK, Chan YH, Ng TM, Chua TS et al. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double blind study. J Gastroenterol. 2006;41(7):647-53.
Luther J, Higgins PDR, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs.triple therapy for primary treatment of Helicobacter pylori Infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73.
Goddard AF, Mohamed JJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology. 1996;111:358-67.
Hoogerwerf WA, Pasricha PJ. In: Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. Bruton LL, Lazo JS, Parker KL. Editors. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw hill, New York. 2001:978-80.
Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Rodo E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for helicobacter pylori eradication: the HYPER study. Gut. 2007;56:475-9.
Myllyluoma E, Kajander K, Mikkola H, Kyrönpalo S,Rasmussen M, Kankuri E, et al. Probiotic intervention decreases serum gastrin-17 in Helicobacter pylori infection. Dig Liver Dis. 2007;39:516-23.
Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La 1 on Helicobacter pylori colonization in children. Nutrition. 2003;19:716-21.
Iwanaga Y, Miyashita N, Saito T, Morikawa K, Itoh Z. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Jpn J Pharmacol. 1996;71:129-37.
Tong JL, Ran ZH, Shen J, Zhang CX and Xiao SD, Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy, Aliment Pharmacol Ther. 2007;25,155-68.
Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, et al. Triple therapies plus different probiotics for helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 2008;12:251-6.
Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. Placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354:832-40.
Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion. 2001;63(1):1-7.
Boer WA, Tytgat GNJ. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol. 1995;30:401-7.
Marteau P, Rambaud JC. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev. 1993;12:207-20.
Nord CE, Heimdal A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis suppl. 1986;49:64-72.
Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin, plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori infected patients. J Antimicrob Chemother. 1999;44:629-40.